|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Treatment with the DPP-4 inhibitor KR62436 (KR) promoted primary tumor growth and lung metastasis in a 4T1 tumor allograft mouse model; DPP-4 knockdown in 4T1 cells displayed similar phenotypes <i>in vivo</i> and <i>in vitro</i>.
|
30584072 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Dipeptidyl peptidase 4 (DPP4) is a cell surface protein that can act as a tumor suppressor or activator, depending upon the level of expression and interaction with the microenvironment and chemokines.
|
31124302 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We found that tumor-associated stroma involving α-SMA-positive myofibroblasts stained negative or negligible for CD26 in 118 out of 193 (61.1%) tumors, whereas noncancerous stromal regions of the breast showed considerable staining for CD26.
|
31140748 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A higher expression of CD26/DPP4 is found in a wide variety of tumor entities, however more research on CD26/DPP4 in the tumor microenvironment is needed to fully explore its use as a tumor biomarker.
|
30822465 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings provide insight into IL-33- and eosinophil-mediated tumor control, revealed when endogenous mechanisms of DPP4 immunoregulation are inhibited.
|
30778250 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This screening method enables us to develop novel anti-human CD26 mAbs suitable for immunohistochemical staining of CD26 in FFPE non-tumor and tumor tissue sections with reliable clarity and intensity.
|
31194830 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These cells reside within the CD34<sup>+</sup> /CD38<sup>─</sup> /Lin<sup>─</sup> fraction and score positive for CD26 (dipeptidylpeptidase IV) a marker, expressed in both bone marrow (BM) and peripheral blood (PB) samples, that discriminates CML cells from normal hematopoietic stem cells (HSCs) or from LSCs of other myeloid neoplasms.
|
30714299 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Novel Antibody-Drug Conjugate with Anti-CD26 Humanized Monoclonal Antibody and Transcription Factor IIH (TFIIH) Inhibitor, Triptolide, Inhibits Tumor Growth via Impairing mRNA Synthesis.
|
31398954 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
DPPIV/CD26 and SerpinB3 were localized in the same tumoral areas and both molecules were correlated with the grade of tumor differentiation, with the highest values detected in GI tumors.
|
29524519 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Together, these results implicate DPP4 as an AR-regulated tumor suppressor gene whose loss enhances growth factor activity and suggest that treatment with DPP4 inhibitors may accelerate emergence of resistance to ADT.<b>Significance:</b> These findings identify DPP4 as an AR-stimulated tumor suppressor gene that is downregulated during progression to castration-resistant prostate cancer, warning that treatment with DPP4 inhibitors, commonly used to treat type 2 diabetes, may accelerate prostate cancer progression following androgen deprivation therapy.<i></i>.
|
30242112 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Interestingly, silencing lncRNA-OIS1 diminished the senescent-associated induction of a nearby gene (Dipeptidyl Peptidase 4, DPP4) with established role in tumor suppression.
|
29481642 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
High DPP4 expression was associated with extrathyroidal extension (P < 0.001), BRAF mutation (P < 0.001), and advanced tumor stage (P = 0.007) in papillary thyroid cancer.
|
28575350 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We hypothesized that this subpopulation of cancer stem cells arises in the late stage of carcinogenesis from the bulk of tumor daughter cells which are CD26-.
|
28545226 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
High CD26 expression in the stroma, but not the tumor itself, was significantly correlated with a poor prognosis.
|
26370256 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover patients with HER2 positive tumors had significantly lower CD26 serum levels (511.8 ± 84.8 pg/mL) compared with HER2 negative tumors (619.1 ± 109.9 pg/mL, p = 0.006).
|
26471376 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Orthotopic HT-29 xenografts treated with standard CRC chemotherapeutics 5-fluorouracil, irinotecan, or oxaliplatin showed dramatic increases in CD26 compared to untreated tumors.
|
26552750 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In the syngeneic 4T1 metastatic breast cancer model, DPP4 overexpression increased tumour development, whereas treatment with sitagliptin and/or juglone suppressed it.
|
26267432 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The prognostic significance of tumour tissue CD26 expression levels was assessed by univariate and multivariate analyses.
|
24870408 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression of glucagon-like peptide-1 receptor and dipeptidyl peptidase-IV in neuroendocrine neoplasms of the pancreas and gastrointestinal tract.
|
25119061 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Neutral endopeptidase (NEP/CD10) and dipeptidyl peptidase IV (DPP IV/CD26) are both ubiquitous glycopeptidases which play important roles in tumor pathogenesis and development.
|
23686701 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study, we demonstrated that the treatment with YS110 induced nuclear translocation of both cell-surface CD26 and YS110 in cancer cells and xenografted tumor.
|
23638030 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Microarray analysis of glioma cells with forced DPP-IV expression revealed differential expression of several candidate genes not linked to the tumor suppressive effects of DPP-IV in previous studies.
|
22306301 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Pharmacological blockade of CD26, via Sitagliptin, reduced growth of InvEE tumours, while combined inhibition of IL-1α and CD26 delayed tumour onset and reduced tumour incidence.
|
21765471 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CD26, a 110-kDa transmembrane glycoprotein with known dipeptidyl peptidase IV activity, plays a role in tumor development and its expression was reported in various human malignancies.
|
21894438 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In a subcutaneous murine model treated with paclitaxel, on Day 39, the tumor size of the DPPIV-transfected cell-inoculated group was as large as that of the vector-transfected cell-inoculated group.
|
19917055 |
2010 |